# IVA catalysts: Inventiva S.A. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/iva/catalysts

> Inventiva S.A. (IVA) has no upcoming catalysts in this calendar. The latest recorded is the lanifibranor topline data readout, Q4 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, half-year only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for IVA?

Inventiva S.A. (IVA) has no upcoming catalysts in this calendar. The latest recorded is the lanifibranor topline data readout, Q4 2026. Press release filed with the SEC (EX-99): "Following completion of the treatment period, we expect to report topline results in the fourth quarter of 2026." [Calendar and source filings](https://sec-api.dev/companies/iva/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001104659-26-111143, https://www.sec.gov/Archives/edgar/data/1756594/000110465926111143/iva-20260630xex99d1.htm (retrieved 2026-11-12). Last confirmed 2026-11-16T22:20:01.192Z. Cite: https://sec-api.dev/companies/iva/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | Inventiva S.A. |
| Ticker | IVA (Nasdaq) |
| SEC CIK | 1756594 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/iva |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| June 13, 2023 | [Lanifibranor topline data readout](https://sec-api.dev/pdufa/lanifibranor) | IVA | NAFLD and T2D | completed, positive | "On June 13, 2023, the Company announced positive topline results from the investigator-initiated Phase II clinical trial evaluating lanifibranor in patients with T2D and NAFLD." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1756594/000110465926040704/iva-20251231x20f.htm)) |
| June 13, 2023 | [Lanifibranor trial start](https://sec-api.dev/pdufa/lanifibranor) | IVA | NAFLD and T2D | completed | "On June 13, 2023, the Company announced positive topline results from the investigator-initiated Phase II clinical trial evaluating lanifibranor in patients with T2D and NAFLD." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1756594/000110465926040704/iva-20251231x20f.htm)) |
| November 6, 2023 | [Lanifibranor trial start](https://sec-api.dev/pdufa/lanifibranor) | IVA | T2D and NAFLD sponsored | completed | "On November 6, 2023, the Company announced a late breaker abstract that presents results from the investigator-initiated Phase II clinical trial evaluating lanifibranor in patients with T2D and NAFLD sponsored by Dr. Cusi at the University of Florida." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1756594/000110465926040704/iva-20251231x20f.htm)) |
| June 2, 2026 | [Lanifibranor FDA approval](https://sec-api.dev/pdufa/lanifibranor) | IVA |  | completed, approved | "On June 2, 2026, we entered into a subscription agreement with funds and accounts managed by BlackRock and Claret Capital Partners (the "Lenders") providing for the issuance of new senior secured debt instruments for an aggregate committed principal amount of up to €130.0 million, plus an additional uncommitted tranche of up to €20.0 million subject to mutual consent following FDA approval of the NDA for lanifibranor (the "Subscription Agreement") (together, the "Debt Financing Transaction")." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1756594/000110465926111143/iva-20260630xex99d1.htm)) |
| 2H 2026 | [SO-2024 topline data readout](https://sec-api.dev/pdufa/so-2024) | IVA |  | scheduled | "The publication of the topline results of the part 1 of the NATiV3 trial is targeted for the second half of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1756594/000110465925094101/iva-20250630xex99d1.htm)) |
| September 29, 2026 | [Lanifibranor primary completion](https://sec-api.dev/pdufa/lanifibranor) | IVA | NASH - Nonalcoholic Steatohepatitis | completed | "NCT04849728 (A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-09-29 (ACTUAL); Lead Sponsor Inventiva Pharma." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04849728)) |
| Q4 2026 | [Inventiva S.A. topline data readout](https://sec-api.dev/companies/iva/catalysts) | IVA |  | scheduled | "Expected Topline Readout Q4 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1756594/000110465926111143/iva-ex99d3.htm)) |
| Q4 2026 | [Inventiva S.A. topline data readout](https://sec-api.dev/companies/iva/catalysts) | IVA |  | scheduled | "Topline results of the Phase 3 NATiV3 clinical trial are expected in the fourth quarter of 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1756594/000110465926111143/iva-ex99d2.htm)) |
| Q4 2026 | [Lanifibranor topline data readout](https://sec-api.dev/pdufa/lanifibranor) | IVA | with MASH | scheduled | "Following completion of the treatment period, we expect to report topline results in the fourth quarter of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1756594/000110465926111143/iva-20260630xex99d1.htm)) |

## Drugs

- [Lanifibranor](https://sec-api.dev/pdufa/lanifibranor): nafld and t2d, t2d and nafld, non-alcoholic fatty liver disease, or nafld, and t2d, t2d and nafld sponsored, with mash with moderate and advanced fibrosis, with topline results, with mash, NASH - Nonalcoholic Steatohepatitis
- [SO-2024](https://sec-api.dev/pdufa/so-2024): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/iva/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "IVA catalysts: Inventiva S.A. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/iva/catalysts

```bibtex
@misc{secapidev_companies_iva_catalysts_20261116,
  title        = {IVA catalysts: Inventiva S.A. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/iva/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_iva_catalysts_20261116","title":"IVA catalysts: Inventiva S.A. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/iva/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
